Company: DMAC
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001437749-25-026207
Chunk: 23

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 4
Chunk 23
---

ITEM 4.   CONTROLS AND PROCEDURES
---------------------------------
Evaluation of Disclosure Controls and Procedures 
 
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the United States Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
 
There was no change in our internal control over financial reporting that occurred during the six months ended June 30, 2025 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.
 
 20

PART II-   OTHER INFORMATION
----------------------------

ITEM 4.   MINE SAFETY DISCLOSURES
---------------------------------
 
Not applicable.